Art. -Nr.: HY-P0210

Copy Link Print Information

DAMGO

13 Cited Publications

Kundenbewertung

Based on 13 publication(s) in Google Scholar

DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.82%
CAS. Nr.: 78123-71-4
Formel: C₂₆H₃₅N₅O₆
Molecular Weight:513.59

Speicherung:

Sealed storage, away from moisture and light.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

DAMGO Chemical Structure

CAS. Nr.: 78123-71-4

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

DAMGO is a μ-opioid receptor (μ-OPR ) selective agonist with a K_d of 3.46 nM for native μ-OPR^[1].

IC₅₀ & Target

μ Opioid Receptor/MOR

Alle Opioid Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	13.7 nM Compound: DAMGO	Stimulation of [35S]GTP-gamma-S, binding to recombinant human Opioid receptor mu 1 expressed in CHO cells Stimulation of [35S]GTP-gamma-S, binding to recombinant human Opioid receptor mu 1 expressed in CHO cells	[PMID: 12672258]
CHO	EC₅₀	4365 nM Compound: DAMGO	Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells. Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.	[PMID: 12672258]
CHO	EC₅₀	>10000 nM Compound: DAMGO	Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells. Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells.	[PMID: 12672258]
CHO	EC₅₀	110 nM Compound: DAMGO	Activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay Activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	[PMID: 16392810]
CHO	EC₅₀	37 nM Compound: DAMGO	Inhibition of [35S]GTP-gamma-S binding to rat mu opioid receptor expressed in CHO cells Inhibition of [35S]GTP-gamma-S binding to rat mu opioid receptor expressed in CHO cells	[PMID: 16509592]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	[PMID: 16942039]
CHO	EC₅₀	110 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding	[PMID: 17276685]
CHO	EC₅₀	110 nM Compound: DAMGO	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	[PMID: 17407276]
CHO	EC₅₀	110 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins	[PMID: 17433695]
CHO	ED₅₀	42 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay Agonist activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S assay	[PMID: 17625813]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay Agonist activity at human mu opioid receptor expressed in CHO cell membrane by [35S]GTPgammaS binding assay	[PMID: 17935988]
CHO	EC₅₀	40 nM Compound: DAMGO	Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	[PMID: 18380425]
CHO	EC₅₀	55 nM Compound: DAMGO	Activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 18417347]
CHO	EC₅₀	1.7 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 18637671]
CHO	EC₅₀	55 nM Compound: DAMGO	Activity at human cloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Activity at human cloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 19027293]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19091564]
CHO	EC₅₀	2.66 nM Compound: DAMGO	Activity at CCK2R-MOPR coexpressed in CHO cells co-transfected with delta-6-Galphaqi4-myr assessed as intracellular calcium release by FLIPR Activity at CCK2R-MOPR coexpressed in CHO cells co-transfected with delta-6-Galphaqi4-myr assessed as intracellular calcium release by FLIPR	[PMID: 19113864]
CHO	EC₅₀	45.06 nM Compound: DAMGO	Activity at monocloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Activity at monocloned mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 19199782]
CHO	EC₅₀	45.1 nM Compound: DAMGO	Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation [35S]GTPgammaS binding relative to basal level Agonist activity against mu opioid receptor expressed in CHO cells assessed as stimulation [35S]GTPgammaS binding relative to basal level	[PMID: 19217280]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19282177]
CHO	ED₅₀	42 nM Compound: DAMGO	Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 3 hrs by liquid scintillation counting Agonist activity at human recombinant mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 3 hrs by liquid scintillation counting	[PMID: 19627147]
CHO	ED₅₀	42 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 20055417]
CHO	ED₅₀	8940 nM Compound: DAMGO	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 20055417]
CHO	IC₅₀	2 nM Compound: DAMGO	Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cell membrane Displacement of [3H]naloxone from mu opioid receptor expressed in CHO cell membrane	[PMID: 20426456]
CHO	EC₅₀	37 nM Compound: DAMGO, [D-Ala2,NMePhe4,Gly5-ol]enkephalin	Agonist activity at rat mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding Agonist activity at rat mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 21128594]
CHO	EC₅₀	110 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding by scintillation counting	[PMID: 21351746]
CHO	EC₅₀	35.3 nM Compound: DAMGO, MOP	Partial agonist activity at human MOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting Partial agonist activity at human MOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting	[PMID: 21866885]
CHO	EC₅₀	6.86 nM Compound: DAMGO, MOP	Partial agonist activity at human DOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting Partial agonist activity at human DOP receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting	[PMID: 21866885]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting	[PMID: 22439881]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting Agonist activity at human mu opioid receptor expressed in CHO cells assessed as [35S]GTPgammaS binding after 60 mins by scintillation counting	[PMID: 23142613]
CHO	EC₅₀	55 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting Agonist activity at human mu opioid receptor expressed in CHO cell membrane assessed as stimulation of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting	[PMID: 23434225]
CHO	ED₅₀	34 nM Compound: DAMGO	Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 3 hrs by liquid scintillation counting analysis Agonist activity at human recombinant mu opioid receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 3 hrs by liquid scintillation counting analysis	[PMID: 23618710]
CHO	EC₅₀	5.6 nM Compound: DAMGO	Agonist activity at mouse cloned mu opioid receptor expressed in CHO cells after 60 mins by [35S]GTPgammaS binding assay Agonist activity at mouse cloned mu opioid receptor expressed in CHO cells after 60 mins by [35S]GTPgammaS binding assay	[PMID: 24103580]
CHO	EC₅₀	32.6 nM Compound: DAMGO	Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis Agonist activity at human mu opioid receptor transfected in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding after 60 mins by scintillation counting analysis	[PMID: 24657054]
CHO	EC₅₀	81 nM Compound: DAMGO	Agonist activity at rat mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at rat mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 25221662]
CHO	EC₅₀	7.57 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human MOR expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 25248680]
CHO	EC₅₀	7.5 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cells assessed as increase in intracellular Ca2+ level after 30 mins by microplate reader analysis Agonist activity at human MOR expressed in CHO cells assessed as increase in intracellular Ca2+ level after 30 mins by microplate reader analysis	[PMID: 25783191]
CHO	EC₅₀	9.61 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cells assessed as increase in intracellular Ca2+ level after 30 mins by cytosensor micrometer Agonist activity at human MOR expressed in CHO cells assessed as increase in intracellular Ca2+ level after 30 mins by cytosensor micrometer	[PMID: 25783191]
CHO	IC₅₀	2.5 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay Agonist activity at human MOR expressed in CHO cells assessed as induction of membrane potential change measured every 3 secs for 30 secs by fluorescent membrane potential assay	[PMID: 26789491]
CHO	IC₅₀	4.3 x 10^-10 M Compound: DAMGO	Displacement of [3H]DAMGO from human recombinant Mu-type opioid receptor expressed in CHO cells Displacement of [3H]DAMGO from human recombinant Mu-type opioid receptor expressed in CHO cells	[PMID: 26988801]
CHO	EC₅₀	30 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay Agonist activity at human MOR expressed in CHO cell membranes after 60 mins by [35S]GTP-gamma-S binding assay	[PMID: 27096047]
CHO	EC₅₀	19 nM Compound: DAMGO	Agonist activity at mouse mu opioid receptor-1 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis Agonist activity at mouse mu opioid receptor-1 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis	[PMID: 27556704]
CHO	EC₅₀	19.7 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay	[PMID: 30996778]
CHO	EC₅₀	0.088 μM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cells by cAMP assay Agonist activity at human mu opioid receptor expressed in CHO cells by cAMP assay	[PMID: 31147104]
CHO	EC₅₀	19 nM Compound: DAMGO	Agonist activity at mouse mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP formation incubated for 8 min followed by forskolin stimulation by ELISA Agonist activity at mouse mu opioid receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP formation incubated for 8 min followed by forskolin stimulation by ELISA	[PMID: 31782922]
CHO	EC₅₀	7.2 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay Agonist activity at human MOR expressed in CHO cell membranes incubated for 1 hr by [35S]-GTPgammaS coupling assay	[PMID: 31834798]
CHO	EC₅₀	23 nM Compound: DAMGO	Agonist activity at human MOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay Agonist activity at human MOR expressed in CHO cell membranes after 1 hr by [35S]GTPgammaS binding assay	[PMID: 32435376]
CHO	EC₅₀	25.5 nM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay Agonist activity at human mu opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay	[PMID: 32530286]
CHO	IC₅₀	3 nM Compound: DAMGO	Binding affinity against rat mu-opioid receptor expressed in CHO cells by competitive inhibition of 1 nM [3H]DAMGO Binding affinity against rat mu-opioid receptor expressed in CHO cells by competitive inhibition of 1 nM [3H]DAMGO	[PMID: 9873480]
CHO-K1	IC₅₀	0.02 μM Compound: DAMGO	Displacement of [3H]Diprenorphine from human recombinant mu opioid receptor expressed in CHOK1 cells after 60 mins Displacement of [3H]Diprenorphine from human recombinant mu opioid receptor expressed in CHOK1 cells after 60 mins	[PMID: 23403082]
HEK293	EC₅₀	8.2 nM Compound: 11, DAMGO	Activity at mu opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding Activity at mu opioid receptor expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding	[PMID: 19683449]
HEK293	IC₅₀	3.18 nM Compound: DAMGO	Agonist activity at mu opioid expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation Agonist activity at mu opioid expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation	[PMID: 20599386]
HEK293	EC₅₀	3.18 nM Compound: DAMGO	Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting Agonist activity at human MOR expressed in HEK293 cell membrane assessed as inhibition of forskolin-induced cAMP accumulation by by liquid scintillation counting	[PMID: 21978284]
HEK293	EC₅₀	3.04 nM Compound: DAMGO	Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter Agonist activity at mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation after 30 mins by liquid scintillation counter	[PMID: 22724433]
HEK293	EC₅₀	3.04 nM Compound: DAMGO	Agonist activity at FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by liquid scintillation counting analysis Agonist activity at FLAG-tagged mu-type opioid receptor (unknown origin) expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 30 mins by liquid scintillation counting analysis	[PMID: 23477419]
HEK293	EC₅₀	378 nM Compound: DAMGO	Agonist activity at GFP-fused mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay Agonist activity at GFP-fused mu opioid receptor (unknown origin) expressed in HEK293 cells assessed as recruitment of beta-arrestin-2 after 10 mins by BRET assay	[PMID: 24613457]
HEK293	IC₅₀	0.005 μM Compound: DAMGO	Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production after 30 mins by HTRF assay Agonist activity at human mu opioid receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production after 30 mins by HTRF assay	[PMID: 25087049]
HEK293	IC₅₀	19.3 nM Compound: DAMGO	Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by EIA method Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation by EIA method	[PMID: 27607020]
HEK293	IC₅₀	0.0051 μM Compound: DAMGO	Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced adenylyl cyclase-mediated cAMP accumulation after 30 mins by HTRF assay Agonist activity at human MOR expressed in HEK293 cells assessed as inhibition of forskolin-induced adenylyl cyclase-mediated cAMP accumulation after 30 mins by HTRF assay	[PMID: 27776274]
HEK293	IC₅₀	4.3 x 10^-10 M Compound: DAMGO	Displacement of [3H]DAMGO from human recombinant mu-opioid receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method Displacement of [3H]DAMGO from human recombinant mu-opioid receptor expressed in HEK293 cells measured after 120 mins by scintillation counting method	[PMID: 27876250]
HEK293-A	EC₅₀	1 nM Compound: DAMGO	Activation of human mu opioid receptor expressed in HEK293a cells by [35S]GTP-gamma-S binding assay Activation of human mu opioid receptor expressed in HEK293a cells by [35S]GTP-gamma-S binding assay	[PMID: 17616524]
HEK293-A	EC₅₀	1 nM Compound: DAMGO	Activation of human mu opioid receptor expressed in HEK293a cells coexpressing YFP-labelled alphai1 and CFP-labelled beta-1-gamma-2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal at 10 uM Activation of human mu opioid receptor expressed in HEK293a cells coexpressing YFP-labelled alphai1 and CFP-labelled beta-1-gamma-2 Gi subunits assessed as decrease in fluorescence resonance energy transfer signal at 10 uM	[PMID: 17616524]
SH-SY5Y	IC₅₀	1.1 nM Compound: DAMGO	Potency for inhibition of forskolin-stimulated cyclic AMP accumulation in SH-SY5Y cells Potency for inhibition of forskolin-stimulated cyclic AMP accumulation in SH-SY5Y cells	[PMID: 12036366]

In Vitro

DAMGO (1-10 μM) significantly reduces the activation of neuronal Akt and ERK1/2 by CXCL12 and inhibits CXCL12-promoted neuronal survival, but does not down-regulate CXCR4 protein expression^[2].
DAMGO (1 μM) effectively inhibits the prostaglandin E 2 (PGE 2) induced increase in a tetrodotoxin-resistant voltage-gated Na⁺ current (TTX-R I _Na), i.e. PGE 2 (1 μM) can increase the TTX-R I _Na peak by 103 % compared to 24.9 % with the addition of DAMGO^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

DAMGO (i.v., 0.5-2 mg/kg) can produce significant anti-injury effects on injured paws of male Sprague-Dawley rats weighing 200-225 g in a dose-dependent manner, producing an effective and long-lasting analgesic effect^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 78123-71-4
Appearance Solid
Molecular Weight 513.59
Formel C₂₆H₃₅N₅O₆
Color White to off-white
Sequence

Tyr-{d-Ala}-Gly-{Me-Phe}-Gly-ol
Sequence Shortening

Y-{d-Ala}-G-{Me-Phe}-G-ol
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture and light

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (13)

All RT-PCRBio/Physico-chemical AssayIF

Sort by:

Journal Impact Factor

Nature

A µ-opioid receptor superagonist analgesic with minimal adverse effects. [Abstract]

2026 Apr;652(8112):1393-1404. PMID: 41922775
Nature

Structural snapshots capture nucleotide release at the μ-opioid receptor. [Abstract]

2025 Dec;648(8094):755-763. PMID: 41193810
Cell

Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets. [Abstract]

2026 Apr 30;189(9):2612-2632.e24. PMID: 42030928
Cell

Structures of the entire human opioid receptor family. [Abstract]

2023 Jan 19;186(2):413-427.e17. PMID: 36638794
Cell

Molecular recognition of morphine and fentanyl by the human μ-opioid receptor. [Abstract]

2022 Nov 10;185(23):4361-4375.e19. PMID: 36368306
Brain

Distinct contribution of spinal neuropeptide Y and NPY1R neurons to morphine analgesia. [Abstract]

2026 Feb 25:awag077. PMID: 41738433
Alzheimers Res Ther

Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer's disease by regulating microglia homeostasis and inhibiting HMGB1 pathway. [Abstract]

2025 Feb 1;17(1):35. PMID: 39893485
J Med Chem

2026 Mar 5;69(6):6508-6527.
Cell Rep Methods

Profiling human iPSC-derived sensory neurons for analgesic drug screening using a multi-electrode array. [Abstract]

2025 May 19;5(5):101051. PMID: 40367946
Aquaculture

2025 Apr 15.

DAMGO purchased from MedChemExpress. Usage Cited in: Aquaculture. 2025 Apr 15.

Transcript levels of agrp, drd1 and drd2 in glucose and DAMGO stimulation (20 μM; 24 h). DAMGO treatment eliminated the increased expression of drd2 induced by glucose stimulation.

DAMGO purchased from MedChemExpress. Usage Cited in: Aquaculture. 2025 Apr 15.

Fluorescence levels of AgRP and c-Fos in glucose and DAMGO (20 μM) or SCK-39394 stimulation for 24 h. DAMGO treatment rescued the decreased immunoreactivity of Agrp and c-Fos proteins suppressed by glucose.
Seoul National University

2024 Feb.

DAMGO purchased from MedChemExpress. Usage Cited in: Seoul National University. 2024 Feb.

The effect of DAMGO (0.1-1000 nM) on forskolin (3 μM)-induced cAMP production was measured using a GloSensor cAMP assay. DAMGO induced μOR activation and effectively inhibited forskolininduced cAMP production.
bioRxiv

Gz Enhanced Signal Transduction assaY (GZESTY) for GPCR deorphanization. [Abstract]

2024 Jul 26:2024.07.26.605282. PMID: 39091869

DAMGO purchased from MedChemExpress. Usage Cited in: bioRxiv. 2024 Jul 26:2024.07.26.605282. [Abstract]

Representative kinetics of cAMP accumulation in response to agonist stimulation of indicated GPCRs using DAMGO (1 μM; 25 min). Application of DAMGO revealed a robust accumulation of intracellular cAMP as measured using a split-luciferase GloSensor.
bioRxiv

2022 Jul 11.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 100 mg/mL (194.71 mM)

DMSO : 33.33 mg/mL (64.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9471 mL

9.7354 mL

19.4708 mL

5 mM

0.3894 mL

1.9471 mL

3.8942 mL

10 mM

0.1947 mL

0.9735 mL

1.9471 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Protokoll

Cell Assay^[2]

Neurons (9 days in vitro) are treated with DAMGO (10 μM) for 24 h in their original culture dish, subsequently transferred to a dish containing Mg²⁺-free saline with glycine (15 μM), and exposed to NMDA (100 μM) and/or CXCL12 (20 nM) in absence of glia. After treatments, neurons are moved back into the original culture dishes containing glia. Neuronal death is evaluated after 24 h. Hoechst 33342 (3 μg/mL) combined with cleaved caspase-3 (1:100) staining is used to identify normal and apoptotic cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. FEBS Lett. 1995 Jan 2;357(1):93-7. Onogi T, et al. DAMGO, a mu-opioid receptor selective agonist, distinguishes between mu- and delta-opioid receptors around their first extracellular loops. [Content Brief]

[2]. Patel JP, et al. Modulation of neuronal CXCR4 by the micro-opioid agonist DAMGO. J Neurovirol. 2006 Dec;12(6):492-500. [Content Brief]

[3]. Gold MS, et al. DAMGO inhibits prostaglandin E2-induced potentiation of a TTX-resistant Na+ current in rat sensory neurons in vitro. Neurosci Lett. 1996 Jul 12;212(2):83-6. [Content Brief]

[4]. Desmeules JA, et al. Selective opioid receptor agonists modulate mechanical allodynia in an animal model of neuropathic pain. Pain. 1993 Jun;53(3):277-285. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	1.9471 mL	9.7354 mL	19.4708 mL	48.6770 mL
	5 mM	0.3894 mL	1.9471 mL	3.8942 mL	9.7354 mL
	10 mM	0.1947 mL	0.9735 mL	1.9471 mL	4.8677 mL
	15 mM	0.1298 mL	0.6490 mL	1.2981 mL	3.2451 mL
	20 mM	0.0974 mL	0.4868 mL	0.9735 mL	2.4338 mL
	25 mM	0.0779 mL	0.3894 mL	0.7788 mL	1.9471 mL
	30 mM	0.0649 mL	0.3245 mL	0.6490 mL	1.6226 mL
	40 mM	0.0487 mL	0.2434 mL	0.4868 mL	1.2169 mL
	50 mM	0.0389 mL	0.1947 mL	0.3894 mL	0.9735 mL
	60 mM	0.0325 mL	0.1623 mL	0.3245 mL	0.8113 mL
H₂O	80 mM	0.0243 mL	0.1217 mL	0.2434 mL	0.6085 mL
H₂O	100 mM	0.0195 mL	0.0974 mL	0.1947 mL	0.4868 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

DAMGO

13 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

DAMGO

Peptide Library

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) DAMGO

Alle Opioid Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

DAMGO

Peptide Library

MCE Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) DAMGO

Alle Opioid Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (13)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

DAMGO Related Classifications

Art. -Nr.: HY-P0210